MeMed

#SuspectedSepsis in patients ❔Question: Can MeMed BV® be used to diagnose sepsis?  ✔️ Answer: Although MeMed BV is not indicated for the diagnosis of Sepsis, current guidelines emphasize the importance of promptly assessing the likelihood and cause of infection in suspected sepsis patients. MeMed BV demonstrates high accuracy in distinguishing between bacterial and viral infections in this specific patient population and may help in rapid assessment of infection etiology with a result within 15 minutes of blood draw. https://lnkd.in/dw_T7DrY References: 1. Angel et al. Annals of Emergency Medicine 2023, 2. Chambliss et al. Clinical Chemistry 2023, 3. Bracken et al. Current pediatric reports 2023 *Suspected sepsis patient defined as ≥2 age-adjusted SIRS criteria (a surrogate marker for possible sepsis)

"When the patients' evaluation is inconclusive, MeMed BV provides us an extra level of information to suspect whether their infection is bacterial or viral and treat it accordingly." Dr. Christian Moya, M.D., Surepoint Medical Centers. At Surepoint Medical Centers, Dr. Moya has experienced firsthand how MeMed BV enhances clinical utility, bringing clarity in uncertain situations. This innovative solution improved patient satisfaction and contributed to combating antibiotic resistance. Discover how this innovative tool is empowering clinicians worldwide. 🧷[Learn more at https://lnkd.in/dRQ-yQz5] #HealthcareInnovation #AntibioticStewardship #BetterOutcomes

The FDA on Tuesday granted breakthrough device designation to MeMed Severity, a test that assesses sepsis risk through protein measurement, providing results in under 15 minutes to support emergency care decisions, offering rapid results to categorize patients based on the level of care they may need. This is a significant step forward in managing one of the most challenging and time-sensitive conditions in medicine. Let’s continue to support advancements that enhance decision-making and save lives! #Diagnostics #SepsisManagement #PatientCare #MeMedSeverity Read full article below: https://lnkd.in/dq-eUs5g

#Sepsis impacts 1.7 million Americans yearly, with 350,000 hospital cases leading to death or hospice care. Survivors often face severe long-term effects. MeMed is proud to share the FDA recently granted the Breakthrough Device Designation to #MeMedSeverity, a test that assesses risk for deterioration to severe outcome in #suspectedsepsis patients using host response technology. With the CDC advancing sepsis management and hospitals increasing dedicated programs, tools like this are crucial for improving outcomes and saving lives. *This device is currently in development and has not been approved for sale by any regulatory authority. https://lnkd.in/d692dhQG

MeMed is thrilled to share that MeMed Severity has been granted the prestigious FDA Breakthrough Device Designation (BDD)! This recognition is not only a testament to our relentless innovation but also a reflection of MeMed Severity’s potential to transform patient care. With MeMed Severity, we are revolutionizing sepsis management—delivering real-time risk stratification, 72-hour prognostication, and actionable outcomes, all seamlessly integrated into existing workflows. This milestone strengthens our position as a global leader in host-response diagnostics, driving innovation to improve healthcare outcomes worldwide. A huge thank you to the incredible team at MeMed for making this possible. Together, we’re shaping the future of patient care. #Innovation #Healthcare #SepsisManagement #Diagnostics #MeMedSeverity *This device is currently in development and has not been approved for sale by any regulatory authority. https://lnkd.in/dK4UQrab

🚨 A common scenario in the ED: A young boy presents with a seasonal fever. Is it bacterial or viral? Will antibiotics be necessary, or can they be avoided? This is a real-life case that has been simplified and anonymized for presentation purposes, offering a glimpse into the critical decision-making process healthcare professionals face every day. Dive into the details and explore how clinical reasoning, host-response technology, and patient-centered care come together to determine the outcome. Let's discuss: How do you approach such cases? Share your insights below! #Healthcare #EmergencyMedicine #ClinicalCases #AntibioticsStewardship https://lnkd.in/dpMcQwDa

"I think that MeMed BV sets us apart by allowing us to tell the patient with some degree of certainty this is a viral infection vs. a bacterial infection. Pretty soon I'm sure Memed BV will be on every pediatric protocol." Learn how MeMed BV is bringing value to one of the leading urgent care center groups across Mississippi. Hear firsthand from Dr. Kristi Trimm on how this solution has enhanced clinical utility, improved patient satisfaction, and reduced uncertainty and unnecessary antibiotic use. #HealthcareInnovation #UrgentCare #MeMedBV #PatientCare #ClinicalUtility #AntibioticStewardship

🦃 Happy Thanksgiving from MeMed! 🍁 We're grateful for the opportunity to test and impact the lives of thousands of patients each year. Each test brings us closer to transforming diagnostics and improving health outcomes. Here’s to a year of innovation and shared success! #Thanksgiving #HealthcareInnovation #MeMed #Hostresponse

Discover how our innovative immune response technology is setting a new benchmark in differentiating bacterial from viral infections. This success story by Innovation World Cup at #MEDICA highlights how MeMed's groundbreaking approach is shaping the future of diagnostics and improving patient outcomes. https://lnkd.in/eRPkwY-3 #MedTech #InnovationLeadership #HealthcareTransformation #MeMed

We're #hiring a new Quality Assurance Expert in Haifa District. Apply today or share this post with your network.